EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

RaPID Selection of Backbone Macrocyclic Peptides Targeting Akt2

Koki Shinbara, Ekishin Yanagi, Ayaka Aizawa, Takayuki Katoh, Hiroaki Suga iD

Angewandte Chemie International Edition · 18.05.2026 · 65 (21)

DOI: 10.1002/anie.7837067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 06.04.2026. Verfasst von Koki Shinbara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Graduate School of Science, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Peptides, Cyclic, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS), Japan Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backbone‐cyclic peptides (BMPs) are an attractive class of molecules appeared in diverse natural bioactive products. However, mRNA display technology coupled with ribosomal synthesis is intrinsically inapplicable to such peptide phenotypes due to loss of the C‐terminal peptide region linking to the mRNA genotypes. To overcome this issue, we have devised a new strategy to link the sidechain‐to‐S‐mainchain bond via an S ‐to‐ N acyl‐shift to connect BMPs to the C‐terminal fragment of the peptide. Here, we report the application of this strategy to construct a library of BMPs fused to cognate mRNAs. The library was applied for the selection of BMP ligands targeting Akt2, which is involved in the signal pathway to cancer pathogenesis. Consequently, BMP ligands against Akt2 were successfully uncovered from the library. The most potent Akt2 inhibitor, BMPakti‐3, showed 1.3 nM of dissociation constant and 34 nM of half‐maximal inhibitory concentration (IC 50 ). This system offers a unique platform for the de novo discovery of bioactive BMP ligands against various protein targets of interest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktPeptides, CyclicProtein Kinase InhibitorsHumansLigandsPeptide Library

Stichwörter der Autor:innen

backbone macrocyclic peptidesgenetic code reprogramminghead‐to‐tail macrocyclic peptidesin vitro screeningpeptide librarypeptides

Substanzen

Proto-Oncogene Proteins c-aktPeptides, CyclicAKT2 protein, humanLigandsPeptide LibraryProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Chemistry, Graduate School of Science, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

ORCID-Profile: Hiroaki Suga

Förderung

  • Japan Society for the Promotion of Science (JSPS)
  • Japan Science and Technology Agency

Zitieren

APA

Shinbara, K., Yanagi, E., Aizawa, A., Katoh, T., & Suga, H. (2026). RaPID Selection of Backbone Macrocyclic Peptides Targeting Akt2. Angewandte Chemie International Edition, 65(21). https://doi.org/10.1002/anie.7837067

Vancouver

Shinbara K, Yanagi E, Aizawa A, Katoh T, Suga H. RaPID Selection of Backbone Macrocyclic Peptides Targeting Akt2. Angewandte Chemie International Edition. 2026;65(21). doi:10.1002/anie.7837067

BibTeX
@article{Shinbara2026,
  author = {Shinbara, Koki and Yanagi, Ekishin and Aizawa, Ayaka and Katoh, Takayuki and Suga, Hiroaki},
  title = {RaPID Selection of Backbone Macrocyclic Peptides Targeting Akt2},
  journal = {Angewandte Chemie International Edition},
  year = {2026},
  volume = {65},
  number = {21},
  doi = {10.1002/anie.7837067}
}
Kostenlos starten →